Home
|
Inbox
|
Search
|
View Abstract
Drug Resistance Patterns in Extrapulmonary Tuberculosis: A Retrospective Study of Seven Hospitals in Korea, 2010-2014
Description
.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A1148 - Drug Resistance Patterns in Extrapulmonary Tuberculosis: A Retrospective Study of Seven Hospitals in Korea, 2010-2014
Author Block: J. Mok1, B. Kang2, H. Kim3, S. Lee4, T. Lee5, H. Lee6, Y. Cho4, D. Jeon7; 1Pusan National University Hospital, Busan, Korea, Republic of, 2Dong-A University Hospital, Busan, Korea, Republic of, 3Inje University Haeundae Paik Hospital, Busan, Korea, Republic of, 4Gyeongsang National University Hospital, Jinju, Korea, Republic of, 5Ulsan University Hospital, Ulsan, Korea, Republic of, 6Inje University Busan Paik Hospital, Busan, Korea, Republic of, 7Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of.
Background: There are limited data on the drug resistance status of patients with extrapulmonary tuberculosis (EPTB). This study was conducted to investigate the resistance rates to anti-TB drugs and the patterns of resistance in patients with EPTB in Korea. The resistance rates of EPTB and pulmonary tuberculosis (PTB) were also compared. Methods: Phenotypic drug susceptibility test (DST) results from patients with culture-confirmed TB treated at seven university-affiliated tertiary care hospitals in Korea from January 2010 to December 2014 were retrospectively reviewed. Results: Of the 5599 patients (53.2 ± 21.2 years old; 58.3% male) included in the study, 5279 (94.3%) had PTB and 320 (5.7%) EPTB. Among the latter, the pleura was the most commonly involved site (n=115, 35.9%). Rates of resistance to first-line drugs in EPTB were 10.9% for isoniazid, 4.4% for rifampin (RIF), 3.4% for ethambutol, and 2.2% for pyrazinamide. Any-drug-resistant, multidrug-resistant (MDR), and extensively drug-resistant TB accounted for 13.1%, 3.8%, and 0.9%, respectively, of the EPTB cases. The resistance rates to RIF (4.4% vs. 7.6%, p = 0.034) and rifabutin (RFB; 2.2% vs. 5.5%, p = 0.010) were significantly lower in EPTB than in PTB patients, as was the proportion of MDR-TB (3.8% vs. 6.9% in the PTB group, p = 0.028). Although the rate of MDR-TB decreased during the study period for both EPTB and PTB, a decreasing trend in the resistance rate in terms of each anti-TB drug was observed only for PTB, not EPTB. Conclusion: In Korea, RIF and RFB resistance rates and the proportion of MDR-TB cases were lower in EPTB than in PTB. To achieve TB control and determine the resistance status of EPTB, nationwide drug susceptibility testing for EPTB is warranted.
Author Block: J. Mok1, B. Kang2, H. Kim3, S. Lee4, T. Lee5, H. Lee6, Y. Cho4, D. Jeon7; 1Pusan National University Hospital, Busan, Korea, Republic of, 2Dong-A University Hospital, Busan, Korea, Republic of, 3Inje University Haeundae Paik Hospital, Busan, Korea, Republic of, 4Gyeongsang National University Hospital, Jinju, Korea, Republic of, 5Ulsan University Hospital, Ulsan, Korea, Republic of, 6Inje University Busan Paik Hospital, Busan, Korea, Republic of, 7Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of.
Background: There are limited data on the drug resistance status of patients with extrapulmonary tuberculosis (EPTB). This study was conducted to investigate the resistance rates to anti-TB drugs and the patterns of resistance in patients with EPTB in Korea. The resistance rates of EPTB and pulmonary tuberculosis (PTB) were also compared. Methods: Phenotypic drug susceptibility test (DST) results from patients with culture-confirmed TB treated at seven university-affiliated tertiary care hospitals in Korea from January 2010 to December 2014 were retrospectively reviewed. Results: Of the 5599 patients (53.2 ± 21.2 years old; 58.3% male) included in the study, 5279 (94.3%) had PTB and 320 (5.7%) EPTB. Among the latter, the pleura was the most commonly involved site (n=115, 35.9%). Rates of resistance to first-line drugs in EPTB were 10.9% for isoniazid, 4.4% for rifampin (RIF), 3.4% for ethambutol, and 2.2% for pyrazinamide. Any-drug-resistant, multidrug-resistant (MDR), and extensively drug-resistant TB accounted for 13.1%, 3.8%, and 0.9%, respectively, of the EPTB cases. The resistance rates to RIF (4.4% vs. 7.6%, p = 0.034) and rifabutin (RFB; 2.2% vs. 5.5%, p = 0.010) were significantly lower in EPTB than in PTB patients, as was the proportion of MDR-TB (3.8% vs. 6.9% in the PTB group, p = 0.028). Although the rate of MDR-TB decreased during the study period for both EPTB and PTB, a decreasing trend in the resistance rate in terms of each anti-TB drug was observed only for PTB, not EPTB. Conclusion: In Korea, RIF and RFB resistance rates and the proportion of MDR-TB cases were lower in EPTB than in PTB. To achieve TB control and determine the resistance status of EPTB, nationwide drug susceptibility testing for EPTB is warranted.
|
Home
|
Inbox
|
Search
|